| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000029307 |
| Receipt No. | R000033502 |
| Official scientific title of the study | Efficacy and safety of pilocarpine / sodium alginate formulation for dry mouth in Sjogren's syndrome patients |
| Date of disclosure of the study information | 2017/09/27 |
| Last modified on | 2017/09/27 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Efficacy and safety of pilocarpine / sodium alginate formulation for dry mouth in Sjogren's syndrome patients | |
| Title of the study (Brief title) | Efficacy and safety of pilocarpine / sodium alginate formulation for dry mouth in Sjogren's syndrome patients | |
| Region |
|
|
| Condition | ||
| Condition | Sjogren's syndrome | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study aims at assessment of the efficacy and safety of a new pilocarpine / sodium alginate solution as a symptomatic treatment for dry mouth in Sjogren's syndrome. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Salivary flow before and 60 minutes after administration |
| Key secondary outcomes | Subjective symptom of oral dryness
Adverse events |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Pilocarpine / sodium alginate solution (0.32 mL, pilocarpine 0.96 mg) is administered intra-orally 3 times a day for 7 days. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Diagnosed as Sjogren's syndrome
2. Aged 16 years-old or more 3. With Salivary flow lower than 2 grams or less per 2 minutes 4. Having symptoms of oral dryness 5. Having submitted written informed consent |
|||
| Key exclusion criteria | 1. Patients with ischemic heart disease
2. Patients with asthma or chronic obstructive airway disease 3. Patients with gastrointestinal obstruction or bladder neck obstruction 4. Patients with epilepsy 5. Patients with parkinsonism or Parkinson's disease 6. Patients with iritis 7. Patients with hypersensitivity on pilocarpine or arginine 8. Patients administered with pilocarpine hydrochloride within 6.5 hours 9. Patients administered with cevimeline hydrochloride hydrate within 20 hours 10. Patients administered with anetholtrithion within 9.5 hours 11. Patients judged by a physician to be inappropriate for inclusion in the study for any other reason |
|||
| Target sample size | 50 | |||
| Research contact person | |
| Name of lead principal investigator | Yoshinori Komagata |
| Organization | Teikyo University |
| Division name | School of Medicine |
| Address | 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan |
| TEL | 03-3964-1211 |
| komagata@med.teikyo-u.ac.jp | |
| Public contact | |
| Name of contact person | Machiko Watanabe |
| Organization | Teikyo University |
| Division name | Faculty of Pharma-Science |
| Address | 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan |
| TEL | 03-3964-1211 |
| Homepage URL | |
| wmachiko@pharm.teikyo-u.ac.jp | |
| Sponsor | |
| Institute | Teikyo University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Teikyo University |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 帝京大学医学部附属病院(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033502 |